Belhaven Biopharma — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Belhaven Biopharma is a private, pre-revenue biotech developing Nasdepi®, a novel dry powder epinephrine nasal spray for the emergency treatment of anaphylaxis. Currently in clinical trials, the product aims to address significant shortcomings of existing epinephrine auto-injectors, including needle phobia, poor global access, and sensitivity to extreme temperatures. The company is targeting a large and underserved global market of individuals at risk for severe allergic reactions, with a value proposition centered on accessibility, ease of use, and stability.

Allergy & ImmunologyEmergency Medicine

Technology Platform

Patented nasal drug delivery platform for rapid systemic administration of dry powder epinephrine, emphasizing needle-free use, heat stability, and intuitive passive device design.

Opportunities

Nasdepi® addresses a large treatment gap created by needle phobia and device complexity, potentially improving adherence among the millions at risk for anaphylaxis.

Its heat-stable, dry-powder format uniquely positions it for global expansion into low- and middle-income countries where auto-injectors are unavailable or impractical due to cold-chain requirements.

Risk Factors

The company faces significant clinical risk in proving bioequivalence to injectable epinephrine, a high regulatory bar for a life-saving intervention.

As a pre-revenue, single-asset private company, it is also highly dependent on raising substantial capital to complete development and faces future commercialization competition against entrenched auto-injector brands.

Competitive Landscape

Belhaven competes directly with dominant epinephrine auto-injectors like Viatris's EpiPen, Kaleo's Auvi-Q, and generic alternatives. It also faces potential competition from other novel delivery approaches in development (e.g., sublingual films, intradermal patches). Its primary differentiation is the combination of needle-free delivery and superior temperature stability.

More companies in Drug Delivery & Formulation →More companies in United States →